LENSAR

LENSAR Gross Margin

The Gross Margin of LENSAR (LNSR) as of Oct 16, 2026 is 46.41 %. In the previous year, Gross Margin was 48.33 % — a change of -3.95% (lower).

Gross Margin

46.41 %

YoY

-3.95%

Last updated:

Gross Margin of LENSAR is 2025 46.41 % . Gross Margin of LENSAR was 2024 48.33 % . It decreases by -3.95% lower compared to the previous year.

LENSAR's gross margin stands at 46.4%, down from 51.8% several years earlier.

The LENSAR Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
39.41 USD
Jan 1, 2019
43.33 USD
Jan 1, 2020
53.35 USD
Jan 1, 2021
51.75 USD
Jan 1, 2022
56.44 USD
Jan 1, 2023
50.06 USD
Jan 1, 2024
48.33 USD
Jan 1, 2025
46.41 USD
The LENSAR Gross Margin history
YEARGross MarginYoY
46.41 %-3.95%
48.33 %-3.46%
50.06 %-11.30%
56.44 %+9.05%
51.75 %-3.00%
53.35 %+23.12%
43.33 %+9.96%
39.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LENSAR Stock analysis

What does LENSAR do? LENSAR Inc is a healthcare company based in Orlando, Florida, specializing in femtosecond laser technology for refractive cataract surgery. The company went public on September 21, 2020, and currently employs 150 full-time employees. LENSAR develops and markets femtosecond laser systems designed to treat cataracts and manage pre-existing or surgically induced corneal astigmatism. Its primary products include the LENSAR Laser System, which features Streamline IV and IntelliAxis technologies, along with associated consumable components such as a disposable patient interface device kit. The company also offers the ALLY Adaptive Cataract Treatment System, a compact device integrating femtosecond laser capabilities with enhanced laser features for single-room cataract procedures. LENSAR's technology aims to assist surgeons in achieving optimal visual outcomes during cataract surgery. The company operates within the healthcare sector, focusing on innovative solutions for ophthalmic procedures. Its headquarters in Orlando serves as the central hub for research, development, and business operations. LENSAR's website, lensar.com, provides further details about its products and services. The firm's product portfolio emphasizes precision and efficiency in surgical treatments, targeting healthcare providers seeking advanced tools for cataract management. As a publicly traded entity under the ticker LNSR, LENSAR continues to advance its technological offerings in the medical device industry. LENSAR is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LENSAR stock

Gross Margin of LENSAR is 46.41 % in 2025.

Gross Margin of LENSAR changed from 48.33 % to 46.41 %, representing a -3.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin LENSAR since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's LENSAR with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — LENSAR

All Key Metrics — LENSAR